NCT07467148

Brief Summary

The aim of this study is to evaluate the placental thickness-to-fetal weight ratio as a predictor of adverse pregnancy outcomes.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
41mo left

Started Aug 2026

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 8, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 12, 2026

Completed
5 months until next milestone

Study Start

First participant enrolled

August 1, 2026

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2029

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2029

Last Updated

March 12, 2026

Status Verified

March 1, 2026

Enrollment Period

3 years

First QC Date

March 8, 2026

Last Update Submit

March 8, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • The rate of occurrence of adverse pregnancy outcomes, including IUGR, preterm birth, low birth weight, fetal distress, NICU admission, or perinatal mortality

    Correlation of placental thickness-to-fetal weight ratio with individual adverse pregnancy outcomes

    From aug 2026 to aug 2029

Eligibility Criteria

Age20 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Hospital

You may not qualify if:

  • Multiple pregnancies (twins, triplets,etc.) Known congenital fetal anomalies Maternal chronic medical conditions affecting fetal growth (e.g pre-existing diabetes, hypertension, renal disease) Intrauterine fetal demise Inability or refusal to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • 1.Burton GJ and Jauniaux E. The human placenta: new perspectives on its formation and function during early pregnancy. Proc Biol Sci. 2023;290(13):202-8. 2. Aye IL, Tong S, Charnock-Jones DS and Smith GC. The human placenta and its role in reproductive outcomes revisited. Physiol Rev. 2025;12(2):25-30. 3. Patel SY, Akileswaran C and Basu S. Early detection of high risk pregnancies using clinical and social data to improve health outcomes. npj Digit Public Health. 2026;10(1):3-10. 4. Wang X, Xiao F and Li J. Intrapartum ultrasound monitoring in second-stage Labor: Impact on delivery outcomes. J Radiat Res Appl Sci. 2025;18(4):105-10. 5. Farahbod F, Zarean E, Khanjani S, Moezzi M, Mohammadizadeh F and Shabanian S. Relationship between placental thickness, grading, and heterogeneity in fetal growth restriction in the third trimester of pregnancy by ultrasonography and pathology tests and their relationship with estimated fetal weight and neonatal outcome. Immunopathol Persa. 2023;10(2):39471-6. 6. Li H, Cheng W, Wen J, Peng J, Wu S, Zhao Y, et al. Clinical analysis of prophylactic uterine artery embolization combined with double balloon catheter for second-trimester pregnancy termination in cases of complete placenta previa: A retrospective study. Medicine. 2023;102(47):362-9. 7. Redline RW, Roberts DJ, Parast MM, Ernst LM, Morgan TK, Greene MF, et al. Placental pathology is necessary to understand common pregnancy complications and achieve an improved taxonomy of obstetrical disease. Am J Obstet Gynecol. 2023;228(2):187-202. 8. Manna C, Lacconi V, Rizzo G, De Lorenzo A and Massimiani M. Placental dysfunction in assisted reproductive pregnancies: perinatal, neonatal and adult life outcomes. Int J Mol Sci. 2022;23(2):659-62. 9. Chow LY, Williams EE, Patel D-S and Battersby C. Perinatal optimisation: the role of the multi-disciplinary team. OB-GYN 2025;22(1):25-30. 10. Lwanga SK, Lemeshow S. Sample size determination in health studies: a practical manual. Geneva: World H

    RESULT

Central Study Contacts

Radia Atef Elzokm, Resident doctor

CONTACT

Ahmed Mohamed Abbas, Professor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assiut university

Study Record Dates

First Submitted

March 8, 2026

First Posted

March 12, 2026

Study Start

August 1, 2026

Primary Completion (Estimated)

August 1, 2029

Study Completion (Estimated)

December 1, 2029

Last Updated

March 12, 2026

Record last verified: 2026-03